Market Research Report

Error-Proof Entry, Expert Positioning, and Exploding Growth in Embryonic Stem Cell Products
cover Published by BIOINFORMANT WORLDWIDE, LLC
Published Product code 242923
Content info 126 Pages
Price

Introduction

Abstract

How to profit from emerging opportunities in the embryonic stem cell research product market

Get 126 pages of expert advice and industry leading stem cell market intelligence...plus limited-time bonuses

Executive Summary:

Human embryonic stem cells (hESCs) are stem cells derived from the inner cell mass of a blastocyst, which is a stage reached four to five days post-fertilization. Human embryonic stem cells are the most pluripotent of all stem cell types and can develop into over 200 different cell types of the human body.

Human embryonic stem cells were first derived from mouse embryos in 1981 by Martin Evans and Matthew Kaufman, and independently by Gail R. Martin. In 1995, the first successful culturing of embryonic stem cells from non-human primates occurred at the University of Wisconsin-Madison. Another breakthrough followed at the University of Wisconsin-Madison in November 1998 when a group led by Dr. James Thomson developed a technique to isolate and grow hESCs derived from human blastocysts. Federal funds to support hESC research became available on August 9, 2001, when President Bush announced his decision regarding federal funding for hESC research.

Because of their plasticity and unlimited capacity for self-renewal, hESCs have been proposed for use in wide range of applications, including toxicology testing, tissue engineering, cellular therapies, and basic stem cell biology research. Of particular interest to the medical community is the potential for use of hESCs to heal tissues with naturally limited capacity for renewal, such as the human heart, liver and brain. However, human embryonic stem cell research is heavily encumbered by patents held by the University of Wisconsin's Wisconsin Alumni Research Foundation (WARF), which creates significant challenges for companies seeking to develop new products.

This market research report explores the complex IP landscape affecting development of human embryonic stem cell products, providing clear guidance for companies entering or already within the market, from collaborating with WARF to less costly alternatives - such as circumventing the claims, conducting research off-shore, and developing embryonic stem cell products for other species.

The potential medical advances made possible from the use of human embryonic stem cells (hESC) are huge. These stem cells are able to develop into any of over 200 different cell types. So it's no surprise that the scientific research community is enthusiastically exploring all possibilities.

And where there is significant and growing interest from scientists, there is an opportunity for a company like yours to increase revenue from supplying stem cell products. There is no doubt it's an exciting market in which to expand your product range. But with embryonic stem cells there are serious market entry barriers to consider - namely a complex intellectual property scene.

The report is the only product available anywhere that provides specific intelligence, guidance, and strategies for research supply companies competing within the embryonic stem cell product market.

You'll learn:

  • Key advances in embryonic stem cell research
  • A breakdown of embryonic stem cell research applications, including shared priorities and priorities by segment
  • Embryonic stem cell patent restrictions and opportunties
  • Historical and future growth projections for the embryonic stem cell market
  • Competitive analysis of providers of embryonic stem cell research tools
  • Overview of specialty pharma companies developing embryonic stem cell therapies
  • Overview of toxicology testing legislation impacting use of embryonic stem cells in toxicology applications
  • A breakdown of embryonic stem cell research product categories
  • Suggestions for novel embryonic stem cell research products, including cells, kits, assays, media and reagents
  • Guidance for companies that wish to offer high-demand embryonic stem cell products
  • And much more

This report will help you understand the market entry challenges you face and give you the expert advice to overcome them. Couple this with market leading commercial intelligence data and this report is a must have if you're looking to outcompete your rivals in this expanding and highly profitable market.

Report Statistics
  • Publication Date: June 2012
  • Total Number of Pages: 126
  • Format: PDF

Table of Contents

Table of Contents

I. Background

  • A. Human Embryonic Stem Cells (hESC)
  • B. Brief History
  • C. Use in Treatment of Disease
  • D. Human Embryonic Stem Cell Line Availability

II. Available Stem Cell Lines

  • A. NIH Registry Approved
  • B. Sources of Additional Published hESC Lines
  • C. Sources of Additional Unpublished hESC Lines

III. Applications

  • A. Basic Stem Cell Biology
  • B. Cellular Therapies
    • 1. Overview
    • 2. Heart Regeneration
    • 3. Pancreatic Islet Cell Replacement
    • 4. Neural Regeneration
  • C. Tissue Engineering
  • D. Toxicology Testing

IV. Application Priorities

  • A. Overall
    • 1. Cell-Based Therapies: Greatest shared priority across research community
      • a. Beneficial hESC Characteristics
      • b. hESC Safety Concerns
      • c. hESC Characterization in Vitro
      • d. hESC Characterization in Vivo
    • 2. Toxicology Assessment: Another area of huge potential
      • a. Overview
      • b. Commercial Interest
  • B. By Segment
    • 1. Academic
    • 2. Biotech
    • 3. Pharma

V. Patent Environment

  • A. Landmark hESC Patents: WARF “Composition of Matter” Patents
    • 1. Background
    • 2. Licensing of WARF Patent Rights
      • a. Overview of WARF Licensees
      • b. Most Recent WARF Licensee: Pfizer, Inc. (May 2009)
    • 3. WARF Patent Exemption: Federal Rights to hESC Research
    • 4. U.S. WARF Patent Challenges
    • 5. Circumventing WARF Patent Rights Using Geographic Limitations
  • B. Global Stem Cell Patent Landscape
  • C. U.S. Patents of Importance
    • 1. Geron Corporation Patents
    • 2. Regents of the University of California Patents
    • 3. BresaGen, Inc. Patents
    • 4. Regeneron Pharmaceuticals, Inc.
    • 5. Vanderbuilt University Patents
  • D. Worldwide Patents of Importance
    • 1. ES Cell International PTE Ltd. Patents (Singapore)
    • 2. DNAVEC Research Inc. Patents (Ibaraki, JP)
    • 3. University of Edinburgh Patents (Edinburgh, GB)
  • E. Summary of the hESC Intellectual Property Landscape

VI. Historical and Future Growth Projections

  • A. PubMed Analysis
    • 1. Historical Analysis (Trailing 10 Years)
    • 2. Future Growth Predictions (5-Year Forecasts)
    • 3. Breakdown of ESC Research by Species
  • B. CRISP Analysis
  • C. Patent Analysis
    • 1. All Fields
    • 2. Abstract Only

VII. hESC PRODUCT COMPETITORS

  • A. Cellartis AB
    • 1. Human embryonic stem cell lines
    • 2. Monoclonal Antibodies for hESC Research
    • 3. Differentiated Cell Products
    • 4. Associated hESC products
  • B. Vitrolife
  • C. Tataa Biocenter
  • D. Invitrogen
    • 1. hESC Culture Media & Reagents
    • 2. hESC-qualified Basement Membrane Extract
    • 3. hESC cDNA Libraries
    • 4. hESC Reporter Cells
    • 5. hESC PCR Kits
    • 6. hESC Stem Cell Antibodies
    • 7. hESC Stem Cell Growth Factors
  • E. Stem Cell Technologies
    • 1. hESC Culture Media & Reagents
    • 2. hESC Primary & Secondary Antibodies
  • F. BD Biosciences
  • G. Chemicon
    • 1. hESC Culture Media and Reagents
    • 2. hESC Lines
    • 3. hESC Kits
    • 4. hESC Antibodies
  • H. R&D Systems
  • I. SA Biosciences
  • J. Thermo Scientific
  • K. Australian Stem Cell Centre

VIII. Specialty Pharmaceutical Companies developing hESC Therapies

  • A. Geron
  • B. Novocell
  • C. Cell Cure Neurosciences Ltd
  • D. Cell Dynamics International
  • E. Advanced Cell Technology

IX. Featured Labs (Potential Customers)

  • A. Academic Labs
  • B. Private Labs
  • C. Government Labs
  • D. International Labs

X. Toxicology Testing Legislation

  • 1. European Union to Ban Animal-Testing for Cosmetic Development in 2009
  • 2. Responses to the European Ban on Animal Testing for Cosmetic Development
    • a. Overview
    • b. Skin Irritation
    • c. Eye Irritation
    • d. Skin Sensitisation
    • e. Mutagenicity/Genotoxicity
    • f. Reproductive Toxicity
  • 3. EU Legislation Regarding Animal-Based Testing for Drug Discovery

XI. Product Development Suggestions

  • A. Product Categories
    • 1. hESCs
    • 2. hESC Derivative Cells
    • 3. hESC Reporter Cells
    • 4. hESC Antibodies
    • 5. hESC Characterization & PCR Kits
    • 6. hESC Qualified BME
    • 7. hESC cDNA Libraries
    • 8. hESC Growth Factors
    • 9. hESC Media and Culture Reagents
  • B. Product Ideas & Suggestions
    • 1. Areas of Underdeveloped Competition
    • 2. Mouse ESC Products
    • 3. iPS Cells Products
    • 4. Non-animal-derived Culture Reagents for hESCs
    • 5. Strategic Collaborations
    • 6. Products for generating Pure ESC populations
    • 7. hESC Toxicity Assay Kit

XII. Events of Interest

  • A. Annual Wisconsin Stem Cell Symposium
  • B. World Stem Cells & Regenerative Medicine Congress
  • C. World Stem Cell Summit 2011
  • D. Stem Cells 2011, Achieving Success in Science and Commercialization
  • E. International Society for Stem Cell Research, Upcoming Events
    • 1. Trailing Year (2011)
    • 2. Forward Year (2012)

Error-Proof Entry, Expert Positioning, and Exploding Growth in Embryonic Stem Cell Products published by BIOINFORMANT WORLDWIDE, LLC in June 1, 2012. This report consists of 126 Pages and the price starts from US $ 3495.

The contents of this page may be different from the latest version. Please contact us for details.

Press Release

What Everybody Ought To Know About Embryonic Stem Cell Product Development

May 30th, 2012

Global Information Inc. would like to present a new market research report, "Error-Proof Entry, Expert Positioning, and Exploding Growth in Embryonic Stem Cell Products" by BIOINFORMANT WORLDWIDE, LLC.

Companies interested in developing human embryonic stem cell products have to navigate a risky product environment. Due to the long-standing and controversial patents held by the University of Wisconsins Alumni Research Foundation (WARF), companies have been largely hindered by the intellectual property (IP) environment restricting the development of embryonic stem cell products. However, going where competitors fear to tread means tremendous financial rewards are available for the companies that move boldly forward.

Human embryonic stem cells offer tremendous therapeutic potential, as they can develop into over 200 different cell types. However, up until now, WARF has had the power to largely control what companies can develop embryonic stem cell products and on what terms. With the release of BioInformants report "Error-Proof Entry, Expert Positioning, and Exploding Growth in Embryonic Stem Cell Products," published June 2012, research supply companies can now receive clear guidance for navigating the hazards of embryonic stem cell product development.

The report reveals critical alternatives to traditional WARF licensing, such as moving research overseas, establishing collaborations with companies that are existing WARF licensees, structuring creative negotiating alternatives, developing products for other species  and other breakthrough strategies. According to Lance Breastgoff, BioInformants Head of Project Management, "The report informs research product companies about their options for functioning within this complex IP landscape and expands the range of options they have available."

BioInformants report "Error-Proof Entry, Expert Positioning, and Exploding Growth in Embryonic Stem Cell Products" also offers historical and future growth projections for the embryonic stem cell product market, competitive analysis of existing providers, and detailed assessment of creative strategies for developing high-demand products. This insight is possible, because BioInformant has been the global leader in stem cell industry data since 2006 and is the only producer of market intelligence data specific for the stem cell sector.

Asked about the edge their report will give to research supply companies over the competition, Breastgoff said, "Over the past twelve months, we have witnessed an explosion of interest in bringing human embryonic stem cell products to market. For research product companies, the information in this report has the potential to save you thousands, or even millions of dollars, by allowing you to consider options other than WARF licensing  or alternatively, to empower you with the knowledge to negotiate a better deal."

Back to Top